Pancreatic cancer 2

Common Name(s)

Pancreatic cancer 2

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 2" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 2" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

http://www.pancan.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Pancreatic cancer 2" returned 213 free, full-text research articles on human participants. First 3 results:

Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.
 

Author(s): Min Tu, Haifeng Li, Nan Lv, Chunhua Xi, Zipeng Lu, Jishu Wei, Jianmin Chen, Feng Guo, Kuirong Jiang, Guoxin Song, Wentao Gao, Yi Miao

Journal:

 

Vasohibin 2 (VASH2) has previously been identified as an agiogenenic factor and a cancer related protein. Here we investigated the association of VASH2 expression and chemoresistance in pancreatic cancer.

Last Updated: 22 Mar 2017

Go To URL
Expression and Prognostic Value of Indoleamine 2,3-dioxygenase in Pancreatic Cancer.
 

Author(s): Tao Zhang, Xiang-Long Tan, Yong Xu, Zi-Zheng Wang, Chao-Hui Xiao, Rong Liu

Journal: Chin. Med. J.. 2017 Mar;130(6):710-716.

 

Indoleamine 2,3-dioxygenase (IDO), an enzyme for tryptophan metabolism through the kynurenine pathway, exhibits an immunosuppressive effect and induces immune tolerance in tumor cells. The effects of IDO on pancreatic cancer are poorly understood. This study aimed to investigate the ...

Last Updated: 17 Mar 2017

Go To URL
Clinically determined type of 18F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer.
 

Author(s): Jae Uk Chong, Ho Kyoung Hwang, Jin Ho Lee, Mijin Yun, Chang Moo Kang, Woo Jung Lee

Journal:

 

To investigate the association between clinical PET (positron emission tomography) type and oncologic outcome in resectable pancreatic cancer.

Last Updated: 24 Feb 2017

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Pancreatic cancer 2" returned 5 free, full-text review articles on human participants. First 3 results:

Mitochondrial uncoupling protein 2 and pancreatic cancer: a new potential target therapy.
 

Author(s): Massimo Donadelli, Ilaria Dando, Elisa Dalla Pozza, Marta Palmieri

Journal: World J. Gastroenterol.. 2015 Mar;21(11):3232-8.

 

Overall 5-years survival of pancreatic cancer patients is nearly 5%, making this cancer type one of the most lethal neoplasia. Furthermore, the incidence rate of pancreatic cancer has a growing trend that determines a constant increase in the number of deceases caused by this pathology. ...

Last Updated: 25 Mar 2015

Go To URL
Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase.
 

Author(s): Lawrence M Knab, Paul J Grippo, David J Bentrem

Journal: World J. Gastroenterol.. 2014 Aug;20(31):10729-39.

 

The interplay between inflammation and cancer progression is a growing area of research. A combination of clinical, epidemiological, and basic science investigations indicate that there is a relationship between inflammatory changes in the pancreas and neoplastic progression. Diets ...

Last Updated: 25 Aug 2014

Go To URL
Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands.
 

Author(s): John R Hornick, Dirk Spitzer, Peter Goedegebuure, Robert H Mach, William G Hawkins

Journal: Surgery. 2012 Sep;152(3 Suppl 1):S152-6.

 

One major barrier in the development of pancreas cancer therapeutics is the selective delivery of the drugs to their cellular targets. We have previously developed several sigma-2 ligands and reported the discovery of a component of the receptor for these ligands. Several sigma-2 ...

Last Updated: 21 Aug 2012

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Screening for PDAC in BRCA1/2 Patients
 

Status: Recruiting

Condition Summary: Pancreatic Cancer

 

Last Updated: 8 Apr 2016

Go to URL

Last Updated: 30 Jan 2017

Go to URL
Rucaparib in BRCA1/2 or PALB2 Mutated Pancreatic Cancer
 

Status: Recruiting

Condition Summary: Pancreatic Cancer

 

Last Updated: 3 May 2017

Go to URL